Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Antacid on Febuxostat XR Bioavailability
NCT02382640Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of febuxostat in hyperuricemia and gout (4 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve During the Dosing Interval and 6 more. Started Mar 2015; status: completed.
02
Drugs
febuxostat
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02382640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382640.